登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>Fc gamma RIIIA / CD16a >SCJUR-STF068

Human CD16a (158F) (Luc) Jurkat Reporter Cell Development Service

For research use only.

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required

描述(Description)

The Human CD16a (158F) (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express full length human CD16a (158F) receptor (Gene ID: 2214) exhibiting a lower affinity for IgG1 and IgG3 isotypes compared to CD16a-158V, which can use to evaluate ADCC activity of antibodies in the presence of corresponding target cells. When co-cultured with a target cell and relevant antibody, the antibody simultaneously binds the target cell antigen and CD16a (158F) receptor on the surface of Human CD16a (Luc) (158F) Jurkat Reporter Cell, resulting in receptor clustering, intracellular signaling and NFAT-mediated luminescence.

应用说明(Application)

• Determination of ADCC activity induced by antibodies.

Fc gamma RIIIA / CD16a Assay Principles

生长特性(Growth Properties)

Suspension

筛选标记(Selection Marker)

Puromycin (5 μg/mL) + Hygromycin (20 μg/mL)

培养基(Complete Growth Medium)

RPMI-1640 + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

Receptor Assay

Fc gamma RIIIA / CD16a FACS

Expression analysis of human CD16a (158F) on Human CD16a (158F) (Luc) Jurkat Reporter Cell by FACS.
Human CD16a (158F) (Luc) Jurkat Reporter Cell or negative control cell were stained with PE-labeled Anti-Human CD16a antibody.

Protocol

 

Application

Fc gamma RIIIA / CD16a APPLICATION

ADCC response to anti-human CD20 antibody (RLU).
Anti-human CD20 antibody-induced ADCC activity was evaluated using Human CD16a (158F) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The EC50 of anti-human CD20 antibody was approximately 0.03 μg/mL.

Protocol

Fc gamma RIIIA / CD16a APPLICATION

ADCC response to anti-human CD20 antibody (Fold).
Anti-human CD20 antibody-induced ADCC activity was evaluated using Human CD16a (158F) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The max induction fold was approximately 275.

Protocol

 

Passage Stability

Fc gamma RIIIA / CD16a PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human CD16a (158F) (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of Anti-human CD20 antibody in the presence of Raji cells. Anti-human CD20 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 8-25.

Protocol

如有相关细胞池需求请联系我们

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and increasing its efficacy would improve cancer immunotherapy. CD16a is a receptor for the Fc portion of IgGs and is responsible to trigger NK cell-mediated ADCC. Acrobiosystems offers a series of NFAT (Luc) Jurkat Reporter Cell specifically designed to assess the potency of specific immunoglobulin for (antibody-dependent cellular cytotoxicity) and (antibody-dependent cell-mediated phagocytosis). These cells derive from the human T lymphocyte Jurkat cell line and stably express CD16 or CD32, two Fc-gamma receptors (FcγR) for the constant region of immunoglobulin G (IgG).

Limited Use&License Disclosure

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

  1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
  2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
  3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use . You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
  4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
  5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
  6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

 

前沿进展

Penile metastasis from colon cancer with BRAF V600E mutation treated with BRAF/MEK-targeted therapy plus cetuximab: A case report
Wu, Cheng, Lan et al
World J Gastrointest Oncol (2025) 17 (3), 100152
Abstract: The incidence of colon cancer has been progressively increasing over time, whereas penile metastasis of colon cancer has remained exceedingly uncommon. Since the prognosis for colon cancer with BRAF V600E mutation is relatively unfavorable, further exploration and investigation are still required to develop treatment strategies for such rare cases.About one year after surgery and chemotherapy, a 50-year-old patient with sigmoid colon cancer developed a mass at the base of the patient's penis, accompanied by severe tenderness and pain during urination. With disease progression, multiple metastatic nodules also emerged in other regions of the penis, including the coronal sulcus. The nodules located in the coronal sulcus were excised for histopathological examination. The histopathological findings revealed that the nodules were metastases originating from the sigmoid colon cancer, with a BRAF V600E mutation detected. This prompted a modification of the therapy regimen of cetuximab, dabrafenib and trametinib, which effectively held back the progression of penile metastasis in the patient.Combining the BRAF/MEK-targeted therapy with cetuximab demonstrates a favorable therapeutic response in BRAF V600E-mutated colon cancer with penile metastasis.©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
HER2-targeted therapy in colorectal cancer: a comprehensive review
Benli, Arıkan, Akbulut-Çalışkan
Clin Transl Oncol (2025)
Abstract: Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide. Despite treatment advancements in the last decades, CRC remains heterogeneous with significant clinical and genetic diversity. Human epidermal growth factor receptor 2 (HER2) proto-oncogene plays a critical role, as its amplification or overexpression leading to abnormal cell proliferation and tumorigenesis. HER2 overexpression or amplification is identified in 2-4% of metastatic CRCs (mCRC) patients, representing a potential therapeutic target. It is also associated with resistance against epidermal growth factor receptor (EGFR)-targeted therapies like cetuximab and panitumumab, for treatment of RAS wild-type mCRC. Although HER2-positive mCRC is rare, assessing HER2 levels is important. Furthermore, anti-HER2 therapies exhibited non-toxic profile and high efficacy in chemorefractory cases. This review delves into modern management of anti-HER2 therapies in CRC with a particular focus on recent advances and current knowledge about the prognostic and predictive value of HER2.© 2025. The Author(s).
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment
Kokori, Olatunji, Ogieuhi et al
Int J Clin Oncol (2025)
Abstract: Colorectal cancer (CRC) poses a substantial global health challenge, ranking as the third most commonly diagnosed and second most fatal cancer worldwide. With an increasing incidence, particularly in older populations, CRC demands innovative therapeutic approaches to address the limitations of existing treatments. One critical target in CRC is the KRAS gene, which is frequently mutated and implicated in various cancer-related processes. This narrative review explores the promising role of Sotorasib plus Panitumumab combination therapy in CRC treatment. Combining Sotorasib with Panitumumab, an EGFR antagonist, offers a synergistic approach to comprehensively block KRAS and EGFR pathways, potentially overcoming resistance mechanisms observed in monotherapies. The review discusses the evolution of CRC treatment from traditional chemotherapy to the advent of targeted therapies like Bevacizumab and Cetuximab. It highlights the limitations of existing therapies, including resistance and toxicities, emphasising the urgency for innovative approaches. The CodeBreak clinical trials, specifically CodeBreak 101 and CodeBreak 300, provide a focal point for evaluating the efficacy of Sotorasib plus Panitumumab in patients with refractory KRAS G12C-mutated mCRC. Preliminary results demonstrate significant improvements in progression-free survival (PFS) and objective response rates, suggesting a paradigm shift in CRC treatment. The preliminary findings from the CodeBreak 300 trial signify a transformative impact of Sotorasib plus Panitumumab in refractory KRAS G12C-mutated mCRC. With a notable increase in PFS and objective response rates and a well-tolerated safety profile, this combination therapy emerges as a potential new standard of care. The results present an optimistic outlook for patients resistant to conventional therapies.© 2025. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Dual Potential of Cetuximab Conjugated Hydroxyapatite Zirconium Nanoparticle as Nanocarrier for Radioenhancer in X-Ray Dynamic Therapy and 177Lu-based Radioimmunotherapy of Lung Cancer
Kurniawan, Mahendra, Rizaludin et al
Nanotheranostics (2025) 9 (1), 82-94
Abstract: This study aimed to synthesize cetuximab (CTX) conjugated hydroxyapatite zirconium (HApZr-CTX) as a nanocarrier for active delivery of photosensitizer and therapeutic radionuclide. The system enabled targeted radioenhancer in X-ray dynamic therapy and radioimmunotherapy for lung cancer. The results showed that HApZr-CTX had the main characteristics of hydroxyapatite crystal in X-ray powder diffraction (XRD), with particle size twice bigger, according to DLS-PSA and TEM measurements. Cellular ROS generation was elevated almost three times in A549 cells after being treated using 125 µg/mL HApZr-CTX and irradiated with 5 Gy of X-ray photon compared to untreated cells. The viability of the treated lung cancer cell line decreased after exposure to external radiation. Moreover, as a radioimmunotherapy candidate, 177Lu was successfully loaded into HApZr-CTX nanocarrier and internalized in A549 more than half of the given dose after 0.5 h incubation. [177Lu]Lu-HApZr-CTX was primarily accumulated in the lung organs of healthy mice one-hour post-injection. In conclusion, HApZr-CTX nanoparticles have the potential to be used as a radioenhancer in X-ray dynamic therapy and radioimmunotherapy for lung cancer therapy.© The author(s).
Showing 1-4 of 9352 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Fc gamma RIIIA / CD16a靶点信息
英文全称:Low affinity immunoglobulin gamma Fc region receptor III-A
中文全称:低亲和力免疫球蛋白γFc段受体III-A
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:14详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定